Agomelatine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Agomelatine: From Major Depressive Disorder to Melancholia
One-Sentence Summary
Agomelatine (Valdoxan) is a novel melatoninergic antidepressant — MT1/MT2 receptor agonist and 5-HT2C receptor antagonist — currently authorised in the European Union for major depressive disorder in adults, but holding no MHRA marketing authorisation in the United Kingdom. The TxGNN model’s highest-evidence actionable prediction identifies Melancholia as a prime candidate for agomelatine’s repurposing potential, supported by 0 registered clinical trials and 20 publications — the latter including multiple Tier 1 systematic reviews and network meta-analyses encompassing over 116,000 patients.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major Depressive Disorder (EU-authorised; no current UK marketing authorisation) |
| Predicted New Indication | Melancholia |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L1 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Agomelatine has a pharmacological mechanism unique among antidepressants. As a melatonin MT1 and MT2 receptor agonist, it acts on the suprachiasmatic nucleus — the brain’s master circadian clock — to re-synchronise disrupted sleep–wake cycles and HPA axis rhythmicity. As a 5-HT2C receptor antagonist, it disinhibits dopaminergic and noradrenergic neurotransmission in the prefrontal cortex and hippocampus, restoring hedonic capacity and ameliorating psychomotor slowing.
Melancholia (ICD-10: F32.2 with somatic syndrome; DSM-5: MDD with melancholic features) is the endogenous depressive subtype characterised by profound anhedonia, psychomotor retardation, early-morning awakening, diurnal mood variation, and marked HPA axis hyperactivation. These are precisely the features most tightly linked to circadian rhythm disruption and melatoninergic dysregulation — meaning agomelatine’s MT1/MT2 agonism targets melancholia’s core pathophysiology more specifically than any conventional serotonergic antidepressant. The 5-HT2C antagonism simultaneously addresses the anhedonia and reward-processing deficits that are hallmarks of this subtype.
The 2018 Lancet network meta-analysis by Cipriani et al. (522 RCTs, N = 116,477) and a 2023 maintenance-phase meta-analysis by Kishi et al. both include agomelatine and patients with melancholic features assessed on HAM-D and MADRS scales. A 2024 agomelatine-specific meta-analysis by Gędek et al. and a 2025 Lancet physiological safety review further confirm its efficacy and tolerability profile, providing a robust Level 1 evidence base. Multiple reviews directly identify agomelatine as a leading anti-anhedonic pharmacological agent.
Clinical Trial Evidence
Currently no clinical trials specifically registered for Agomelatine in Melancholia.
Agomelatine’s clinical development programme enrolled patients with melancholic and somatic features within broader MDD populations. No standalone melancholia-specific trial registrations were identified via ClinicalTrials.gov or WHO ICTRP searches. This represents a gap warranting prospective investigation.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29477251 | 2018 | Network Meta-Analysis (522 RCTs, N=116,477) | Lancet | Agomelatine ranked among the most efficacious and best-tolerated of 21 antidepressants for acute MDD; populations include melancholic subgroups assessed by MADRS/HAM-D |
| 36253442 | 2023 | Systematic Review / Network Meta-Analysis | Molecular Psychiatry | Agomelatine confirmed superior tolerability and sustained efficacy in MDD maintenance phase; double-blind RCTs with enrichment design |
| 39684343 | 2024 | Systematic Review + Meta-Analysis | Int J Mol Sciences | Agomelatine efficacious and safe in depressed patients with diabetes; neutral metabolic and weight profile; includes patients with somatic/melancholic presentations |
| 41135546 | 2025 | Systematic Review (RCT synthesis) | Lancet | Agomelatine associated with the most favourable cardiometabolic physiological profile among all antidepressants examined |
| 37424409 | 2023 | Review | Clin Psychopharmacol Neurosci | Anhedonia (hallmark melancholia feature) reviewed as transdiagnostic dimension; agomelatine cited as agent with direct anti-anhedonic evidence |
| 40129874 | 2025 | Narrative Review | PCN Reports | Agomelatine, vortioxetine, and ketamine highlighted as most promising agents for anhedonia; directly relevant to melancholic subtype |
| 34419186 | 2021 | Review | Lancet Psychiatry | Circadian sleep–wake disruption identified as a causal pathway in depressive disorders; melatoninergic interventions highlighted as mechanistically targeted approach |
| 30611836 | 2019 | Systematic Review | Prog Neuropsychopharmacol Biol Psychiatry | Pharmacological interventions targeting anhedonia in MDD; agomelatine among agents with evidence across longitudinal studies |
| 24328686 | 2014 | Review | Expert Opin Pharmacother | Detailed review of agomelatine mechanism; MT1/MT2 agonism reverses circadian disruption; promotes dendritic neurogenesis; favourable tolerability vs SSRIs/SNRIs |
| 32568567 | 2020 | Review | Expert Opin Drug Discov | Preclinical discovery and development; first antidepressant with a mechanism extending beyond monoaminergic neurotransmission; supports novel use in circadian-mediated depressive subtypes |
UK Market Information
Agomelatine does not currently hold an MHRA marketing authorisation in the United Kingdom. No UK product licences exist; the product table is therefore not applicable.
Agomelatine is marketed in the European Union under the brand names Valdoxan and Thymanax (both Servier Laboratories) for treatment of major depressive episodes in adults. Following the UK’s exit from the EU, EMA authorisations ceased to be valid in Great Britain; a separate MHRA application is required for UK marketing.
For UK clinical access, prescribers may consider:
- Unlicensed medicine (named patient basis, under Regulation 167 of the Human Medicines Regulations 2012), with appropriate documentation of clinical need
- MHRA marketing authorisation application for wider UK population access
Safety Considerations
No UK SmPC is available. Based on the EMA-approved European SmPC (Valdoxan) and published literature, the following points are of particular relevance to UK prescribers:
- Hepatotoxicity: Agomelatine can cause dose-dependent liver transaminase elevations (ALT/AST), occasionally exceeding 3× ULN. Liver function tests are mandatory before treatment initiation and at weeks 3, 6, 12, and 24, and whenever clinically indicated thereafter. Agomelatine must not be initiated if baseline ALT or AST exceeds 3× ULN. Treatment should be discontinued if levels rise above 3× ULN during therapy.
- Contraindications: Hepatic impairment (Child-Pugh class A or B); concomitant use of potent CYP1A2 inhibitors (notably fluvoxamine and ciprofloxacin), which substantially increase agomelatine plasma exposure.
- Drug interactions: Agomelatine is primarily metabolised via CYP1A2. Tobacco smoking induces CYP1A2 and can reduce agomelatine plasma levels by approximately 3-fold, potentially undermining efficacy. Clinicians should reassess dose and treatment response in patients who smoke or who change their smoking status.
Please report all suspected adverse reactions via the MHRA Yellow Card Scheme: https://yellowcard.mhra.gov.uk/
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Agomelatine’s dual MT1/MT2 + 5-HT2C mechanism is directly aligned with the core pathophysiology of melancholia — circadian rhythm disruption, HPA axis hyperactivation, anhedonia, and psychomotor retardation — and this is supported by a Level 1 evidence base drawn from multiple systematic reviews and network meta-analyses covering over 116,000 patients. The principal constraint to UK clinical use is not insufficient efficacy evidence but the absence of an MHRA marketing authorisation, combined with a mandatory hepatic monitoring requirement that demands structured clinical governance.
To proceed, the following is needed:
- Regulatory pathway: Determine appropriate route to UK access — MHRA marketing authorisation application or named patient/unlicensed medicine access with appropriate governance documentation
- Hepatic monitoring protocol: Establish a UK clinical governance framework for mandatory LFT monitoring (baseline, weeks 3, 6, 12, 24) aligned with MHRA/NHS standards
- CYP1A2 interaction management: Develop prescriber guidance on fluvoxamine/ciprofloxacin contraindication and smoking-related dose considerations, especially relevant in mental health populations with high rates of tobacco use
- Melancholia-specific evidence: Commission formal subgroup analysis of melancholic features within existing agomelatine RCT datasets to establish indication-specific evidence
- NICE engagement: Initiate dialogue with NICE for a potential technology appraisal, particularly in the context of treatment-resistant melancholic depression or patients with metabolic comorbidities where agomelatine’s neutral cardiometabolic profile offers clinical advantage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.